NRIX Nurix Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NRIX

Price (delayed)

$12.73

Market cap

$625.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.66

Enterprise value

$604.13M

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer ...

Highlights
NRIX's gross profit has soared by 94% YoY and by 5% from the previous quarter
The revenue has soared by 94% YoY and by 5% from the previous quarter
NRIX's debt has surged by 173% year-on-year but it is down by 4.8% since the previous quarter
NRIX's equity is down by 38% year-on-year and by 16% since the previous quarter
NRIX's quick ratio is down by 35% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.nurixtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of NRIX
Market
Shares outstanding
49.15M
Market cap
$625.69M
Enterprise value
$604.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.69
Price to sales (P/S)
8.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.47
Earnings
Revenue
$80.89M
EBIT
-$144.64M
EBITDA
-$130.28M
Free cash flow
-$83.87M
Per share
EPS
-$2.66
Free cash flow per share
-$1.53
Book value per share
$3.45
Revenue per share
$1.47
TBVPS
$5.69
Balance sheet
Total assets
$312.67M
Total liabilities
$143.93M
Debt
$29.16M
Equity
$168.75M
Working capital
$163.35M
Liquidity
Debt to equity
0.17
Current ratio
2.86
Quick ratio
2.79
Net debt/EBITDA
0.17
Margins
EBITDA margin
-161.1%
Gross margin
100%
Net margin
-178.9%
Operating margin
-194.5%
Efficiency
Return on assets
-43.6%
Return on equity
-67.1%
Return on invested capital
-65.3%
Return on capital employed
-64.3%
Return on sales
-178.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NRIX stock price

How has the Nurix Therapeutics stock price performed over time
Intraday
-2.68%
1 week
2.99%
1 month
-14.33%
1 year
35.43%
YTD
23.35%
QTD
-13.4%

Financial performance

How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$80.89M
Gross profit
$80.89M
Operating income
-$157.33M
Net income
-$144.73M
Gross margin
100%
Net margin
-178.9%
NRIX's gross profit has soared by 94% YoY and by 5% from the previous quarter
The revenue has soared by 94% YoY and by 5% from the previous quarter
NRIX's net margin has surged by 58% year-on-year and by 4.3% since the previous quarter
Nurix Therapeutics's operating margin has surged by 56% YoY and by 3.4% QoQ

Growth

What is Nurix Therapeutics's growth rate over time

Valuation

What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
3.69
P/S
8.64
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.47
NRIX's EPS is up by 24% year-on-year
The stock's price to book (P/B) is 68% more than its last 4 quarters average of 2.2
NRIX's equity is down by 38% year-on-year and by 16% since the previous quarter
The revenue has soared by 94% YoY and by 5% from the previous quarter
The stock's price to sales (P/S) is 22% more than its last 4 quarters average of 7.1

Efficiency

How efficient is Nurix Therapeutics business performance
NRIX's return on sales has surged by 58% year-on-year and by 4.4% since the previous quarter
The ROE has contracted by 13% from the previous quarter and by 11% YoY
NRIX's return on invested capital is down by 12% year-on-year and by 9% since the previous quarter
NRIX's return on assets is down by 4.8% since the previous quarter

Dividends

What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRIX.

Financial health

How did Nurix Therapeutics financials performed over time
The total assets is 117% greater than the total liabilities
Nurix Therapeutics's total liabilities has increased by 50% YoY but it has decreased by 7% QoQ
NRIX's current ratio is down by 36% year-on-year and by 16% since the previous quarter
NRIX's debt is 83% smaller than its equity
NRIX's debt has surged by 173% year-on-year but it is down by 4.8% since the previous quarter
NRIX's equity is down by 38% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.